Clinical Trials Directory

Trials / Conditions / Relapsed and Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

13 registered clinical trials studyying Relapsed and Refractory Multiple Myeloma — 1 currently recruiting.

StatusTrialSponsorPhase
WithdrawnMezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT06050512
Kathleen DorritiePhase 1 / Phase 2
RecruitingSelinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05530421
University of MiamiPhase 2
Active Not RecruitingStudy of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749
Kite, A Gilead CompanyPhase 1
TerminatedIPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic
NCT03683277
Intergroupe Francophone du MyelomePhase 2
TerminatedA Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
NCT03710915
HitGen Inc.Phase 1
UnknownStudy of BCMA CAR-T in Multiple Myeloma
NCT03559764
Allife Medical Science and Technology Co., Ltd.EARLY_Phase 1
CompletedRetrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patien
NCT03477643
PETHEMA Foundation—
UnknownBCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
NCT03661554
The Pregene (ShenZhen) Biotechnology Company, Ltd.EARLY_Phase 1
CompletedCarfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Mye
NCT03029234
AmgenPhase 3
TerminatedA Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
NCT02223598
Cleave Biosciences, Inc.Phase 1
CompletedStudy of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple M
NCT02144038
Novartis PharmaceuticalsPhase 1
CompletedStudy of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT00932698
Millennium Pharmaceuticals, Inc.Phase 1
TerminatedEfficacy Study of CYT997 in Multiple Myeloma
NCT00664378
Gilead SciencesPhase 2